{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:28:38Z","timestamp":1791815318930,"version":"4.3.4"},"reference-count":167,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004027","name":"Postdoctoral Foundation of Heilongjiang Province","doi-asserted-by":"publisher","award":["LBH-Z21066"],"award-info":[{"award-number":["LBH-Z21066"]}],"id":[{"id":"10.13039\/501100004027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014889","name":"Harbin University of Commerce","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014889","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bioorg.2025.109040","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:02:35Z","timestamp":1758978155000},"page":"109040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Recent progress in topoisomerase inhibitors as anticancer agents: Research and design strategies for Topo I and II inhibitors via structural optimization"],"prefix":"10.1016","volume":"165","author":[{"given":"Guanghuan","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12943-024-01973-5","article-title":"The senescence journey in cancer immunoediting","volume":"23","author":"Zingoni","year":"2024","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.bioorg.2025.109040_bb0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109040_bb0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/d41573-020-00202-0","article-title":"Addressing cancer's grand challenges","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.109040_bb0025","article-title":"Ten-gram-scale mechanochemical synthesis of ternary lanthanum coordination polymers for antibacterial and antitumor activities","volume":"10","author":"Zhang","year":"2022","journal-title":"Front. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0030","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","article-title":"Notch signaling pathway in cancer: from mechanistic insights to targeted therapies","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109040_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0040","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s00018-024-05495-7","article-title":"The concealed side of caspases: beyond a killer of cells","volume":"81","author":"Abdelghany","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bioorg.2025.109040_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2025.101322","article-title":"From foe to friend: rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor","author":"You","year":"2025","journal-title":"J. Pharmaceutical Anal."},{"key":"10.1016\/j.bioorg.2025.109040_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113993","article-title":"Disorders of cancer metabolism: the therapeutic potential of cannabinoids","volume":"157","author":"Sun","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0055","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3892\/mmr.2024.13387","article-title":"Research progress on antioxidants and protein aggregation inhibitors in cataract prevention and therapy","volume":"31","author":"Wang","year":"2024","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0060","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA topoisomerases: structure, function, and mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu. Rev. Biochem."},{"issue":"5356","key":"10.1016\/j.bioorg.2025.109040_bb0065","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.279.5356.1534","article-title":"A model for the mechanism of human topoisomerase I","volume":"279","author":"Stewart","year":"1998","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.bioorg.2025.109040_bb0070","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.molcel.2024.02.025","article-title":"Mitotic chromosomes are self-entangled and disentangle through a topoisomerase-II-dependent two-stage exit from mitosis","volume":"84","author":"Hildebrand","year":"2024","journal-title":"Mol. Cell"},{"issue":"17","key":"10.1016\/j.bioorg.2025.109040_bb0075","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1016\/j.molcel.2024.07.032","article-title":"RNA interacts with topoisomerase I to adjust DNA topology","volume":"84","author":"Bhola","year":"2024","journal-title":"Mol. Cell"},{"issue":"19","key":"10.1016\/j.bioorg.2025.109040_bb0080","doi-asserted-by":"crossref","first-page":"10608","DOI":"10.1073\/pnas.191321998","article-title":"Human mitochondrial topoisomerase I","volume":"98","author":"Zhang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-biochem-091724-010717","article-title":"Topoisomerase regulation of Cancer gene expression","volume":"94","author":"Baranello","year":"2025","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0090","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41467-021-27686-7","article-title":"Topoisomerase I (TOP1) dynamics: conformational transition from open to closed states","volume":"13","author":"Takahashi","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-56911-w","article-title":"SRBD1 facilitates chromosome segregation by promoting topoisomerase II\u03b1 localization to mitotic chromosomes","volume":"16","author":"Lovejoy","year":"2025","journal-title":"Nat. Commun."},{"issue":"6562","key":"10.1016\/j.bioorg.2025.109040_bb0100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/379225a0","article-title":"Structure and mechanism of DNA topoisomerase II","volume":"379","author":"Berger","year":"1996","journal-title":"Nature"},{"issue":"7173","key":"10.1016\/j.bioorg.2025.109040_bb0105","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/nature06396","article-title":"Structural basis for gate-DNA recognition and bending by type IIA topoisomerases","volume":"450","author":"Dong","year":"2007","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23136-6","article-title":"Structural basis for allosteric regulation of human Topoisomerase IIalpha","volume":"12","author":"Vanden Broeck","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109040_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106548","article-title":"Topoisomerase II inhibitors design: early studies and new perspectives","volume":"136","author":"Swedan","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109040_bb0120","doi-asserted-by":"crossref","first-page":"553","DOI":"10.13005\/bpj\/2396","article-title":"The DNA-topoisomerase inhibitors in cancer therapy","volume":"15","author":"Mastrangelo","year":"2022","journal-title":"Biomed. Pharmacol. J."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-49567-5","article-title":"Topoisomerase I is an evolutionarily conserved key regulator for satellite DNA transcription","volume":"15","author":"Teng","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109040_bb0130","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/17460441.2022.2055545","article-title":"The design and discovery of topoisomerase I inhibitors as anticancer therapies","volume":"17","author":"Martin-Encinas","year":"2022","journal-title":"Expert Opin. Drug Discov."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109040_bb0135","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/1759-7714.13289","article-title":"Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin","volume":"11","author":"Sakurai","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.bioorg.2025.109040_bb0140","series-title":"Implications of Topoisomerase (TOP1 and TOP2\u03b1) expression in patients with breast cancer. in vivo","first-page":"3483","volume":"34","author":"Ogino","year":"2020"},{"key":"10.1016\/j.bioorg.2025.109040_bb0145","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev.bi.58.070189.002031","article-title":"DNA topoisomerase poisons as antitumor drugs","volume":"58","author":"Liu","year":"1989","journal-title":"Annu. Rev. Biochem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109040_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032532","article-title":"A mini review of novel topoisomerase II inhibitors as future anticancer agents","volume":"24","author":"Okoro","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109040_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16121582","article-title":"Precisely tailoring molecular structure of doxorubicin prodrugs to enable stable Nanoassembly, rapid activation, and potent antitumor effect","volume":"16","author":"Feng","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.109040_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117611","article-title":"Topoisomerase II-targeting anticancer clinical candidates and drugs: a critical analysis, unravelling molecular medicinal insights and promising research roadmap","volume":"291","author":"Acharya","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109040_bb0165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1083\/jcb.202209125","article-title":"Cell cycle responses to Topoisomerase II inhibition: molecular mechanisms and clinical implications","volume":"222","author":"Soliman","year":"2023","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bioorg.2025.109040_bb0170","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1146\/annurev.pharmtox.41.1.53","article-title":"Tumor cell death induced by topoisomerase-targeting drugs","volume":"41","author":"Li","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2025.109040_bb0175","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2023.02.019","article-title":"Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?","volume":"185","author":"Dempke","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0180","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/nyas.12358","volume":"1310","author":"Pendleton","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.109040_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113639","article-title":"Camptothecin\u2019s journey from discovery to WHO essential medicine: fifty years of promise","volume":"223","author":"Khaiwa","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0190","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1038\/s41467-025-60167-9","article-title":"Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection","volume":"16","author":"Kubes","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109040_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107412","article-title":"Identification of FTY720 and COH29 as novel topoisomerase I catalytic inhibitors by experimental and computational studies","volume":"147","author":"Zeng","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109040_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/ph16101456","article-title":"Prospects of Topoisomerase inhibitors as promising anti-Cancer agents","volume":"16","author":"Yakkala","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109040_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071824","article-title":"A systematic review of clinical trials on the efficacy and safety of CRLX101 Cyclodextrin-based nanomedicine for Cancer treatment","volume":"15","author":"Serrano-Martinez","year":"2023","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.bioorg.2025.109040_bb0210","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"16","key":"10.1016\/j.bioorg.2025.109040_bb0215","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s40265-016-0650-8","article-title":"Pixantrone: a review in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"76","author":"Keating","year":"2016","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109040_bb0220","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/17460441.2017.1331215","article-title":"The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia","volume":"12","author":"Paubelle","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2000.tb07020.x","article-title":"Mechanism of action of camptothecin","volume":"922","author":"Liu","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109040_bb0230","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1021\/acs.jmedchem.3c02115","article-title":"Unleashing the potential of Camptothecin: exploring innovative strategies for structural modification and therapeutic advancements","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115710","article-title":"The recent developments of camptothecin and its derivatives as potential anti-tumor agents","volume":"260","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109040_bb0240","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/med.21342","article-title":"Perspectives on biologically active camptothecin derivatives","volume":"35","author":"Liu","year":"2015","journal-title":"Med. Res. Rev."},{"issue":"Pt A","key":"10.1016\/j.bioorg.2025.109040_bb0245","article-title":"Anti-tumor effects and mechanism of a novel camptothecin derivative YCJ100","volume":"311","author":"Zhang","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2025.109040_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110309","article-title":"The novel camptothecin derivative, CPT211, induces cell cycle arrest and apoptosis in models of human breast cancer","volume":"128","author":"Chiu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109040_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107723","article-title":"Identification of 7-aminourea or 7-aminothiourea derivatives of camptothecin as selective topoisomerase I inhibitors with anti-colorectal cancer activities","volume":"152","author":"Tu","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0260","article-title":"Design and synthesis of novel 20(S)-alpha-aminophosphonate derivatives of camptothecin as potent antitumor agents","volume":"ed2021","author":"Chen","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111971","article-title":"Design, synthesis and antineoplastic activity of novel 20(S)-acylthiourea derivatives of camptothecin","volume":"187","author":"Yang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109040_bb0270","first-page":"2939","article-title":"Homocamptothecin, an E-ring modified Camptothecin with enhanced lactone stability, retains Topoisomerase I-targeted activity andAntitumor properties","volume":"59","author":"Lesueur-Ginot","year":"1999","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109040_bb0275","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202000068","article-title":"Design, synthesis and biological activity of (20S,21S)-7-Cyclohexyl-21-fluorocamptothecin carbamates as potential antitumor agents","volume":"17","author":"Ma","year":"2020","journal-title":"Chem. Biodivers."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0280","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/10286020.2017.1392941","article-title":"Synthesis and antitumor activity of a series of lactone-opened camptothecin derivatives","volume":"21","author":"Zheng","year":"2019","journal-title":"J. Asian Nat. Prod. Res."},{"issue":"24","key":"10.1016\/j.bioorg.2025.109040_bb0285","doi-asserted-by":"crossref","first-page":"10257","DOI":"10.1021\/jm501100b","article-title":"Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among US FDA approved pharmaceuticals: miniperspective","volume":"57","author":"Vitaku","year":"2014","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109040_bb0290","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.apsb.2022.09.010","article-title":"Benzimidazole and its derivatives as cancer therapeutics: the potential role from traditional to precision medicine","volume":"13","author":"Lee","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.bioorg.2025.109040_bb0295","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300206","article-title":"The medicinal panorama of benzimidazoles and their scaffolds as anticancer and antithrombotic agents: a review","volume":"356","author":"Chalkappa","year":"2023","journal-title":"Arch Pharm (Weinheim)."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0300","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1080\/14756366.2020.1806831","article-title":"Synthesis, anticancer evaluation and molecular docking studies of new benzimidazole- 1,3,4-oxadiazole derivatives as human topoisomerase types I poison","volume":"35","author":"Acar Cevik","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109040_bb0305","first-page":"13359","article-title":"New Benzimidazole-Triazole derivatives as Topoisomerase I inhibitors: design, synthesis, anticancer screening, and molecular modeling studies","volume":"9","author":"Cevik","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2025.109040_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113555","article-title":"Quinoline anticancer agents active on DNA and DNA-interacting proteins: from classical to emerging therapeutic targets","volume":"220","author":"Lauria","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104419","article-title":"Identification of quinoline-chalcones and heterocyclic chalcone-appended quinolines as broad-spectrum pharmacological agents","volume":"105","author":"Atukuri","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113261","article-title":"Discovery of 4-alkoxy-2-aryl-6,7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent in vitro anticancer activity","volume":"215","author":"Elbadawi","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105174","article-title":"Design and synthesis of novel conformationally constrained 7,12-dihydrodibenzo[b,h][1,6] naphthyridine and 7H-Chromeno[3,2-c] quinoline derivatives as topoisomerase I inhibitors: In vitro screening, molecular docking and ADME predictions","volume":"115","author":"Kardile","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116049","article-title":"Camptothecin structure simplification elaborated new imidazo[2,1-b]quinazoline derivative as a human topoisomerase I inhibitor with efficacy against bone cancer cells and colon adenocarcinoma","volume":"265","author":"Khodair","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109040_bb0335","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s12272-020-01283-6","article-title":"Pharmacological effects of harmine and its derivatives: a review","volume":"43","author":"Zhang","year":"2020","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2025.109040_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116061","article-title":"Design, synthesis, and biological evaluation of harmine derivatives as topoisomerase I inhibitors for cancer treatment","volume":"265","author":"Guo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103629","article-title":"Novel diindoloazepinone derivatives as DNA minor groove binding agents with selective topoisomerase I inhibition: design, synthesis, biological evaluation and docking studies","volume":"99","author":"Kadagathur","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107015","article-title":"Design and synthesis of luotonin A-derived topoisomerase targeting scaffold with potent antitumor effect and low genotoxicity","volume":"143","author":"Li","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106638","article-title":"New benzothienopyran and benzothienopyranopyrimidine derivatives as topoisomerase I inhibitors: design, synthesis, anticancer screening, apoptosis induction and molecular modeling studies","volume":"137","author":"Khalil","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0360","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00387","article-title":"How does doxorubicin work?","volume":"1","author":"Patel","year":"2012","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0365","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41514-024-00135-7","article-title":"A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging","volume":"10","author":"Linders","year":"2024","journal-title":"Npj Aging."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109040_bb0370","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0006-2952(01)00522-6","article-title":"Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs","volume":"61","author":"Zunino","year":"2001","journal-title":"Biochem. Pharmacol."},{"issue":"51","key":"10.1016\/j.bioorg.2025.109040_bb0375","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adc9245","article-title":"Circulating hemopexin modulates anthracycline cardiac toxicity in patients and in mice","volume":"8","author":"Liu","year":"2022","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109040_bb0380","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2025.109040_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101205","article-title":"Doxorubicin and other anthracyclines in cancers: activity, chemoresistance and its overcoming","volume":"93","author":"Mattioli","year":"2023","journal-title":"Mol. Asp. Med."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109040_bb0390","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1042\/CS20200301","article-title":"Molecular mechanisms of anthracycline cardiovascular toxicity","volume":"135","author":"Narezkina","year":"2021","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.bioorg.2025.109040_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105925","article-title":"Heterocyclic ring expansion yields anthraquinone derivatives potent against multidrug resistant tumor cells","volume":"127","author":"Tikhomirov","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116103","article-title":"Synthesis and antitumor activity of cyclopentane-fused anthraquinone derivatives","volume":"265","author":"Tikhomirov","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109040_bb0405","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201804452","article-title":"Conjugate of doxorubicin to albumin-binding peptide outperforms Aldoxorubicin","volume":"15","author":"Yousefpour","year":"2019","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0410","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13048-022-01029-6","article-title":"Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.bioorg.2025.109040_bb0415","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejca.2017.09.009","article-title":"First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours","volume":"86","author":"Schoffski","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"15","key":"10.1016\/j.bioorg.2025.109040_bb0420","doi-asserted-by":"crossref","first-page":"13108","DOI":"10.1021\/acs.chemrev.1c00991","article-title":"1, 2, 3-Triazole and its analogues: new surrogates for diazo compounds","volume":"122","author":"Akter","year":"2022","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2025.109040_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.124232","article-title":"Discovery of novel benzenesulfonamides incorporating 1, 2, 3-triazole scaffold as carbonic anhydrase I, II, IX, and XII inhibitors","volume":"239","author":"Buza","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"issue":"25","key":"10.1016\/j.bioorg.2025.109040_bb0430","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0435","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100158","article-title":"1,2,3-Triazole hybrids as anticancer agents: a review","volume":"355","author":"Alam","year":"2022","journal-title":"Arch Pharm (Weinheim)."},{"key":"10.1016\/j.bioorg.2025.109040_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107437","article-title":"Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: design, synthesis, and molecular docking study","volume":"148","author":"El Hamaky","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109040_bb0445","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000237","article-title":"Design and discovery of new 1,2,4-triazolo[4,3-c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors","volume":"354","author":"Alesawy","year":"2021","journal-title":"Arch Pharm (Weinheim)."},{"key":"10.1016\/j.bioorg.2025.109040_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104399","article-title":"Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors","volume":"105","author":"El-Adl","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107158","article-title":"New pyranopyrazole based derivatives: design, synthesis, and biological evaluation as potential topoisomerase II inhibitors, apoptotic inducers, and antiproliferative agents","volume":"144","author":"Sobh","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109040_bb0460","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/jnci\/85.5.388","article-title":"Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the eastern cooperative oncology group results","volume":"85","author":"Chang","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109040_bb0465","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00204-011-0799-6","article-title":"Dominant lethal mutations of topoisomerase II inhibitors etoposide and merbarone in male mice: a mechanistic study","volume":"86","author":"Attia","year":"2012","journal-title":"Arch. Toxicol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109040_bb0470","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1021\/acs.jmedchem.7b01388","article-title":"Pharmacophore hybridization to discover novel Topoisomerase II poisons with promising Antiproliferative activity","volume":"61","author":"Ortega","year":"2018","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109040_bb0475","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1021\/acs.jmedchem.9b01760","article-title":"Design, synthesis, dynamic docking, biochemical characterization, and in vivo pharmacokinetics studies of novel Topoisomerase II poisons with promising Antiproliferative activity","volume":"63","author":"Arencibia","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0480","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2147\/DDDT.S97161","article-title":"Amsacrine analog-loaded solid lipid nanoparticle to resolve insolubility for injection delivery: characterization and pharmacokinetics","volume":"10","author":"Fang","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bioorg.2025.109040_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108096","article-title":"Exploring the therapeutic potential of acridines: synthesis, structure, and biological applications","volume":"155","author":"Marques","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.109040_bb0490","doi-asserted-by":"crossref","DOI":"10.3390\/ph15091098","article-title":"Synthesis and evaluation of Antiproliferative activity, Topoisomerase IIalpha inhibition, DNA binding and non-clinical toxicity of new Acridine-Thiosemicarbazone derivatives","volume":"15","author":"Sousa","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bioorg.2025.109040_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105543","article-title":"Structural optimizations and bioevaluation of N-substituted acridone derivatives as strong topoisomerase II inhibitors","volume":"119","author":"Li","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104913","article-title":"Discovery of 5-(or 6)-benzoxazoles and oxazolo[4,5-b]pyridines as novel candidate antitumor agents targeting hTopo IIalpha","volume":"112","author":"Karatas","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105756","article-title":"Biological activity and ADME\/Tox prediction of some 2-substituted benzoxazole derivatives","volume":"123","author":"Zilifdar Foto","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.109040_bb0510","article-title":"Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines","volume":"9","author":"de Baat","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0515","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2024.2302920","article-title":"Palindromic carbazole derivatives: unveiling their antiproliferative effect via topoisomerase II catalytic inhibition and apoptosis induction","volume":"39","author":"Olszewski","year":"2024","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0520","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ejmech.2018.01.010","article-title":"Synthesis of carbazole derivatives containing chalcone analogs as non-intercalative topoisomerase II catalytic inhibitors and apoptosis inducers","volume":"145","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0525","article-title":"Design, synthesis and biological studies of carbazole-thiosemicarbazone hybrids as potential topoisomerase II catalytic inhibitors","author":"Li","year":"2025","journal-title":"RSC. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114706","article-title":"Discovery of 1,2-diphenylethene derivatives as human DNA topoisomerase II catalytic inhibitors and antitumor agents","volume":"243","author":"Xu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109040_bb0535","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202400175","article-title":"Synthesis of 2-phenylnaphthalenoid amide derivatives and their topoisomerase IIalpha inhibitory and antiproliferative activities","volume":"357","author":"Wu","year":"2024","journal-title":"Arch Pharm (Weinheim)."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109040_bb0540","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1021\/acs.jcim.0c00202","article-title":"Substituted 4,5'-Bithiazoles as catalytic inhibitors of human DNA Topoisomerase IIalpha","volume":"60","author":"Bergant Loboda","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2025.109040_bb0545","first-page":"2995","article-title":"Simulation- and AI-directed optimization of 4,6-substituted 1,3,5-triazin-2(1H)-ones as inhibitors of human DNA topoisomerase IIalpha. Comput Struct","volume":"23","author":"Herlah","year":"2024","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.bioorg.2025.109040_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116676","article-title":"Nature-inspired substituted 3-(imidazol-2-yl) morpholines targeting human topoisomerase IIalpha: Dynophore-derived discovery","volume":"175","author":"Herlah","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0555","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","article-title":"Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents","volume":"22","author":"Doostmohammadi","year":"2024","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0560","doi-asserted-by":"crossref","DOI":"10.3390\/ph16010094","article-title":"The implication of Topoisomerase II inhibitors in synthetic lethality for Cancer therapy","volume":"16","author":"Matias-Barrios","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"22","key":"10.1016\/j.bioorg.2025.109040_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27227993","article-title":"Dual Topoisomerase I\/II inhibition-induced apoptosis and Necro-apoptosis in Cancer cells by a novel ciprofloxacin derivative via RIPK1\/RIPK3\/MLKL activation","volume":"27","author":"Alaaeldin","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.bioorg.2025.109040_bb0570","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1078-0432.CCR-22-3640","article-title":"New life of Topoisomerase I inhibitors as antibody-drug conjugate warheads","volume":"29","author":"Pommier","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109040_bb0575","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/acs.jmedchem.9b00726","article-title":"Dual inhibitors of human DNA Topoisomerase II and other Cancer-related targets","volume":"63","author":"Skok","year":"2020","journal-title":"J. Med. Chem."},{"issue":"35","key":"10.1016\/j.bioorg.2025.109040_bb0580","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.2174\/092986710793361252","article-title":"Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs","volume":"17","author":"Salerno","year":"2010","journal-title":"Curr. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109040_bb0585","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bcp.2012.07.018","article-title":"Berberine: new perspectives for old remedies","volume":"84","author":"Tillhon","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109040_bb0590","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejmech.2022.114376","article-title":"Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer","volume":"237","author":"Deng","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109040_bb0595","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1021\/acs.jmedchem.4c02689","article-title":"Synthesis, structural modification, and Antismall cell lung Cancer activity of 3-Arylisoquinolines with dual inhibitory activity on Topoisomerase I and II","volume":"68","author":"Deng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0600","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bioorg.2024.108043","article-title":"Design, synthesis and anticancer evaluation of 4-substituted 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines as dual topoisomerase I and II inhibitors","volume":"154","author":"Arora","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0605","article-title":"2-(4-Bromobenzyl) tethered 4-amino aryl\/alkyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines: design, synthesis, anticancer assessment via dual topoisomerase-I\/II inhibition, and in silico studies","author":"Arora","year":"2024","journal-title":"RSC. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109040_bb0610","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/molecules14051852","article-title":"Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa","volume":"14","author":"Jiang","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109040_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.113164","article-title":"Evodiamine: a review of its pharmacology, toxicity, pharmacokinetics and preparation researches","volume":"262","author":"Sun","year":"2020","journal-title":"J. Ethnopharmacol."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109040_bb0620","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.phymed.2012.02.003","article-title":"Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells","volume":"19","author":"Pan","year":"2012","journal-title":"Phytomedicine"},{"issue":"4","key":"10.1016\/j.bioorg.2025.109040_bb0625","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.enzmictec.2005.10.029","article-title":"Microbial metabolism of evodiamine by Penicillium janthinellum and its application for metabolite identification in rat urine","volume":"39","author":"Li","year":"2006","journal-title":"Enzym. Microb. Technol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109040_bb0630","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ptr.4766","article-title":"Investigation of the in vitro metabolism of evodiamine: characterization of metabolites and involved cytochrome p450 isoforms","volume":"27","author":"Sun","year":"2013","journal-title":"Phytother. Res."},{"key":"10.1016\/j.bioorg.2025.109040_bb0635","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejmech.2024.116807","article-title":"Identification of a novel 10-hydroxyevodiamine prodrug as a potent topoisomerase inhibitor with improved aqueous solubility for treatment of hepatocellular carcinoma","volume":"279","author":"Wei","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"47","key":"10.1016\/j.bioorg.2025.109040_bb0640","doi-asserted-by":"crossref","first-page":"13513","DOI":"10.1016\/S0040-4020(99)00833-9","article-title":"Calothrixins a and B, novel pentacyclic metabolites from Calothrix cyanobacteria with potent activity against malaria parasites and human cancer cells","volume":"55","author":"Rickards","year":"1999","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bioorg.2025.109040_bb0645","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1023\/A:1025134106985","article-title":"Human cancer cell (Jurkat) killing by the cyanobacterial metabolite calothrixin a","volume":"15","author":"Chen","year":"2003","journal-title":"J. Appl. Phycol."},{"key":"10.1016\/j.bioorg.2025.109040_bb0650","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lfs.2018.12.052","article-title":"Anti-lung cancer activity and inhibitory mechanisms of a novel Calothrixin a derivative","volume":"219","author":"Yang","year":"2019","journal-title":"Life Sci."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109040_bb0655","doi-asserted-by":"crossref","first-page":"8040","DOI":"10.1021\/acs.jmedchem.2c00615","article-title":"Optimization of the natural product Calothrixin a to discover novel dual Topoisomerase I and II inhibitors with improved anticancer activity","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109040_bb0660","first-page":"116","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109040_bb0665","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Cancer J."},{"issue":"Suppl. 3","key":"10.1016\/j.bioorg.2025.109040_bb0670","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.6-suppl_3-5","article-title":"Taxane\/anthracycline combinations: setting a new standard in breast cancer?","volume":"6","author":"Nabholtz","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2025.109040_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115366","article-title":"N (14)-substituted evodiamine derivatives as dual topoisomerase 1\/tubulin-inhibiting anti-gastrointestinal tumor agents","volume":"255","author":"Deng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0680","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1080\/14756366.2022.2072308","article-title":"New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization","volume":"37","author":"Mohammed","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108334","article-title":"Design and development of new substituted pyrimidine hybrids with imidazole and triazole: exploring utility as an anticancer agent via human topoisomerase-II and tubulin inhibition","volume":"158","author":"Yadav","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109040_bb0690","doi-asserted-by":"crossref","DOI":"10.3390\/biom11040603","article-title":"Podophyllotoxin: history, recent advances and future prospects","volume":"11","author":"Shah","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2025.109040_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112870","article-title":"Design, synthesis and screening of benzimidazole containing compounds with methoxylated aryl radicals as cytotoxic molecules on (HCT-116) colon cancer cells","volume":"209","author":"Noha","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109040_bb0700","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.bioorg.2025.109040_bb0705","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/81671","article-title":"Histone deacetylase interacts directly with DNA topoisomerase II","volume":"26","author":"Tsai","year":"2000","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109040_bb0710","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1158\/1535-7163.MCT-05-0194","article-title":"In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates","volume":"4","author":"Marchion","year":"2005","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109040_bb0715","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1074\/jbc.C000824200","article-title":"Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis","volume":"276","author":"Johnson","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109040_bb0720","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1021\/acs.jnatprod.4c00843","article-title":"Semisynthesis of Glycosmis pentaphylla alkaloid derivatives: Pyranoacridone-Hydroxamic acid cytotoxic conjugates with HDAC and Topoisomerase II alpha dual inhibitory activity","volume":"88","author":"Kavya Teja","year":"2025","journal-title":"J. Nat. Prod."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109040_bb0725","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1021\/acs.jmedchem.4c01859","article-title":"Indolo[3,2-c]isoquinoline Hydroxamic acid derivatives as novel orally Topoisomerase-histone deacetylase dual inhibitors for NSCLC therapy","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109040_bb0730","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.jmedchem.4c02135","article-title":"Design and synthesis of topoisomerases-histone deacetylase dual targeted Quinoline-bridged Hydroxamates as anticancer agents","volume":"68","author":"Joshi","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115303","article-title":"Design, synthesis and biological evaluation of dual topo II\/HDAC inhibitors bearing pyrimido[5,4-b]indole and pyrazolo[3,4-d]pyrimidine motifs","volume":"252","author":"Zhao","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109040_bb0740","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10100364","article-title":"Sensitization of Cancer cells to radiation and Topoisomerase I inhibitor Camptothecin using inhibitors of PARP and other signaling molecules","volume":"10","author":"Matsuno","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bioorg.2025.109040_bb0745","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol. Oncol."},{"issue":"18","key":"10.1016\/j.bioorg.2025.109040_bb0750","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810503","article-title":"Combined PARP and dual Topoisomerase inhibition potentiates genome instability and cell death in ovarian Cancer","volume":"23","author":"Florkemeier","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"17\u201318","key":"10.1016\/j.bioorg.2025.109040_bb0755","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1101\/gad.348479.121","article-title":"The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1\/2-deficient cells","volume":"35","author":"Simoneau","year":"2021","journal-title":"Genes Dev."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109040_bb0760","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1517\/13543784.2011.585756","article-title":"Amonafide: a potential role in treating acute myeloid leukemia","volume":"20","author":"Allen","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"4 Pt 2","key":"10.1016\/j.bioorg.2025.109040_bb0765","first-page":"596","article-title":"Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan","volume":"29","author":"Innocenti","year":"2001","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109040_bb0770","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087233","article-title":"Resistance to TOP-1 inhibitors: good old drugs still can surprise us","volume":"24","author":"Kumar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109040_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115598","article-title":"Design, synthesis and development of a dual inhibitor of Topoisomerase 1 and poly (ADP-ribose) polymerase 1 for efficient killing of cancer cells","volume":"258","author":"Guha Majumdar","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109040_bb0780","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ejmech.2024.116348","article-title":"Design, synthesis and biological evaluation of matrine contains benzimidazole derivatives as dual TOPOI and PARP inhibitors for cancer therapy","volume":"270","author":"Qiu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109040_bb0785","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/1947601910377493","article-title":"Targeting MYC expression through G-Quadruplexes","volume":"1","author":"Brooks","year":"2010","journal-title":"Genes Cancer"},{"issue":"20","key":"10.1016\/j.bioorg.2025.109040_bb0790","doi-asserted-by":"crossref","first-page":"9023","DOI":"10.1093\/nar\/gkr612","article-title":"C-MYC promoter G-quadruplex formed at the 5\u2032-end of NHE III 1 element: insights into biological relevance and parallel-stranded G-quadruplex stability","volume":"39","author":"Mathad","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109040_bb0795","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molcel.2021.11.016","article-title":"MYC assembles and stimulates topoisomerases 1 and 2 in a \u201ctopoisome\u201d","volume":"82","author":"Das","year":"2022","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.bioorg.2025.109040_bb0800","doi-asserted-by":"crossref","first-page":"6720","DOI":"10.1021\/acs.jmedchem.0c02202","article-title":"New Dibenzoquinoxalines inhibit triple-negative breast Cancer growth by dual targeting of Topoisomerase 1 and the c-MYC G-Quadruplex","volume":"64","author":"Hu","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109040_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2022.07.014","article-title":"Discovery of novel triple targeting G-quadruplex and topoisomerase 1\/2 ligands from natural products evodiamine and rutaecarpine","volume":"34","author":"Wang","year":"2023","journal-title":"Chin. Chem. Lett."},{"issue":"24","key":"10.1016\/j.bioorg.2025.109040_bb0810","doi-asserted-by":"crossref","first-page":"17572","DOI":"10.1021\/acs.jmedchem.1c01491","article-title":"Design and synthesis of Indenoisoquinolines targeting Topoisomerase I and other biological macromolecules for Cancer chemotherapy","volume":"64","author":"Cushman","year":"2021","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.109040_bb0815","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1021\/acs.jmedchem.3c02303","article-title":"Design, synthesis, and investigation of the pharmacokinetics and anticancer activities of indenoisoquinoline derivatives that stabilize the G-quadruplex in the MYC promoter and inhibit topoisomerase I","volume":"67","author":"Han","year":"2024","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109040_bb0820","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.1021\/acs.jmedchem.1c00100","article-title":"Recent Progress on tubulin inhibitors with dual targeting capabilities for Cancer therapy","volume":"64","author":"Shuai","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109040_bb0825","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14728222.2024.2341630","article-title":"An update on the development on tubulin inhibitors for the treatment of solid tumors","volume":"28","author":"Yakkala","year":"2024","journal-title":"Expert Opin. Ther. Targets"},{"issue":"6","key":"10.1016\/j.bioorg.2025.109040_bb0830","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1021\/acsomega.3c07574","article-title":"Estrone-based derivatives stabilize the c-MYC and c-KIT G-Quadruplex DNA structures","volume":"9","author":"Kumar","year":"2024","journal-title":"ACS. Omega"},{"issue":"3","key":"10.1016\/j.bioorg.2025.109040_bb0835","doi-asserted-by":"crossref","DOI":"10.3390\/ph18030341","article-title":"Recent advancements in the development of HDAC\/tubulin dual-targeting inhibitors","volume":"18","author":"Tran","year":"2025","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825009204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825009204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:27:57Z","timestamp":1762223277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825009204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":167,"alternative-id":["S0045206825009204"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109040","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent progress in topoisomerase inhibitors as anticancer agents: Research and design strategies for Topo I and II inhibitors via structural optimization","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109040"}}